Panacea Biotec Financial Results
- Market cap
- ₹2,122 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹249.48 – ₹467.78
In the Q1 quarter, Panacea Biotec reported revenue of ₹170 crore, and net profit of ₹19.1 crore. The operating margin was 19%. Earnings per share were ₹15.40.
Summary
Panacea Biotec Limited is showing strong operational fundamentals with healthy volume activity and bullish technical indicators.
AI-generated summary of public data — not investment advice · 9 October 2026
Panacea Biotec quarterly results
Consolidated figures, newest quarter first.
| Item | Q1 |
|---|---|
| Revenue | 170 |
| Expenses | 138 |
| Operating profit | 31.84 |
| Operating margin % | 19% |
| Other income | 45 |
| Interest | 12 |
| Depreciation | 35 |
| Profit before tax | 25.47 |
| Tax % | 25% |
| Net profit | 19.1 |
| EPS (₹) | 15.40 |
Panacea Biotec annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | FY25 |
|---|---|
| Revenue | 743 |
| Expenses | 594 |
| Operating profit | 149 |
| Operating margin % | 20% |
| Other income | 180 |
| Interest | 50 |
| Depreciation | 140 |
| Profit before tax | 117 |
| Tax % | 25% |
| Net profit | 87.02 |
| EPS (₹) | 61.60 |
| Dividend payout % | 22% |
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Panacea Biotec financial results — frequently asked questions
What were Panacea Biotec's latest quarterly results?
For the Q1 quarter (consolidated), Panacea Biotec reported revenue of ₹170 crore, operating profit of ₹31.84 crore and net profit of ₹19.1 crore, with EPS of ₹15.40.
What is Panacea Biotec's annual revenue and net profit?
For the financial year ended FY25, Panacea Biotec's revenue was ₹743 crore and net profit ₹87.02 crore.
What is the EPS of Panacea Biotec?
Quarterly EPS for Q1 was ₹15.40. Annual EPS for FY25 was ₹61.60.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Panacea Biotec With ATS
Track PANACEABIO live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.